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.Birth Prevalence of Homocystinuria in Central Europe: Frequency and
Pathogenicity of Mutation c.1105C>T (p.R369C) in the Cystathionine
Beta-Synthase Gene
MIROSLAV JANOšÍK, PHD, JITKA SOKOLOVÁ, MSC, BOHUMILA JANOšÍKOVÁ, PHD, JAKUB KRIJT, PHD, VERONIKA KLATOVSKÁ, MSC, AND
VIKTOR KOžICH, MD, PHD
bjectives To estimate the frequency of the cystathionine beta-synthase deficiency caused by c.1105C>T mutation in
entral Europe compared to Norway, and to examine the pathogenicity of the corresponding p.R369C mutant enzyme.
tudy design Mutation c.1105C>T was analyzed in 600 anonymous Czech newborn blood spots. Catalytic activity and
uaternary structure of the p.R369C mutant was evaluated after expression in 2 cellular systems.
esults Population frequency of the c.1105C>T mutation was 0.005, predicting the birth prevalence of homocystinuria of
:40 000, which increased to 1:15 500 in a model including 10 additional mutations. In Escherichia coli the p.R369C mutant
isfolded, and its activity was severely reduced, and expression in Chinese hamster ovary cells enabled proper folding with
ctivity decreased to 63% of the wild-type enzyme. This decreased activity was not due to impaired Km for both substrates but
esulted from Vmax lowered to 55% of the normal cystathionine beta-synthase enzyme.
onclusions The c.1105C>T (p.R369C) allele is common also in the Czech population. Although the p.R369C mutation
mpairs folding and decreases velocity of the enzymatic reaction, our data are congruent with rather mild clinical phenotype
n homozygotes or compound heterozygotes carrying this mutation. (J Pediatr 2009;154:431-7)
omocystinuria caused by cystathionine beta synthase (CBS) deficiency is a rare autosomal recessive disorder of sulfur
amino acid metabolism. The disease manifests in childhood by vascular, neurologic, and connective tissue abnormal-
ities,1,2 although increasing numbers of mildly affected adults with only thromboembolism are reported.3-6
Various approaches have been used to examine the population frequency of homocystinuria, but the true incidence of the
isease is unknown. Newborn screening, based on finding individuals with elevated blood
ethionine concentrations, has apparently been detected almost exclusively patients with
evere pyridoxine nonresponsive form of disease7 and with a worldwide incidence of
:65 000-1:900 000.8 However, estimates calculated from the heterozygote frequency for
he most common mutation c.833TC (p.I278T) in newborns suggested an incidence of
t least one order of magnitude higher.9-11 In agreement with these findings Refsum et
l12 reported even higher population frequency of another CBS mutation c.1105 CT,
hich was present in 0.8% of CBS chromosomes among unselected Norwegian newborns.
he calculated incidence of homocystinuria caused by 6 mutations including the c.1105
T may be thus unusually high with 1 patient with CBS deficiency expected in each of
400 Norwegian newborns.12
The c.1105 CT mutation is localized in a CpG dinucleotide in exon 10 and leads
o replacement of arginine in position 369 of the CBS polypeptide by cysteine (p.R369C).
he pathogenicity of this mutation is unclear. The c.1105 CT was originally described
n 3 unrelated pyridoxine-responsive patients of Norwegian,14 Dutch,13 and Anglo-
eltic4 origin, which strongly supports the notion of its pathogenicity (Table I). In
ontrast, Kim et al14 showed in a yeast system that expression of the p.R369C variant
nsures normal to above-normal growth of CBS-deficient strain, suggesting none or at
ost a mild effect of p.R369C on the enzyme activity.
BS Cystathionine beta-synthase
HO Chinese hamster ovary
AGE Polyacrylamide gel electrophoresis
SAM S-adenosylmethionine
SAH S-adenosylhomocysteine
SDS Sodium dodecyl sulfate
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4High frequency of the c.1105 CT allele and its pu-
ative pathogenicity may have important epidemiologic con-
equences, such as for neonatal screening of homocystinuria.
ur study was therefore aimed at (1) determining the fre-
uency of this variant in another Caucasian population and
2) examining the pathogenicity of the p.R369C mutant by
xpression studies in prokaryotic and eukaryotic systems.
METHODS
amples
We used 300 anonymous peripheral blood spots from
rague and 300 archived umbilical cord blood samples from
rno representing Bohemian and Moravian region, respec-
ively, from a study that was described previously.10 Genomic
NA was isolated with the QIAamp DNA Mini Kit (Qia-
en, Valencia, California). This study was approved by the
thics Committee of Charles University in Prague—First
aculty of Medicine.
enotyping
To detect the c.1105CT alleles, we used polymerase
hain reaction (PCR)-RFLP technique to amplify exon 10
rom genomic DNA using specific primers—forward: 5=-
AgTgCCCACCCCAgCTCATTA-3= and reverse: 5=-
gCCTCCTCCCCTCCCAgTTCT-3= and Klentaq poly-
able I. Known patients with a CBS deficiency carry
Ancestry Genotype*
Disease
severity
Vita
B
orwegian-sib pair Allele 1: p.R369C
Allele 2: p.I278T
variable among
siblings

nglo-Celtic Allele 1: p.R369C
Allele 2: c.533del18
mild 
utch Both alleles:
[p.R369C;
p.R491C]
severe 
Genotypes of both alleles are shown with description of either cDNA nucleotide chan
This column shows pyridoxine responsiveness; in references 4 and 11 the vitamin B6 r
reatment, respectively.erase (GeneAge Technologies, Praha, Czech Republic). t
32 Janošík et alKim et al14 used HaeII for PCR-RFLP analysis of
.1105 CT (p.R369C); however, the loss of restriction site
n their assay may be also caused by the mutation c.1106
A (p.R369H). To explore the possibility that either
.1105 CT or c.1106 GA was present in Czech newborns,
he PCR products were first digested with HhaI to detect
hese 2 mutant alleles. The HhaI-positive samples were fur-
her digested with Cac8I and DraIII to check for the presence
f c.1105 CT and c.1106 GA mutation, respectively. The
atter mutation was not detected in the studied cohort.
xpression Constructs
Both the wild-type CBS and the mutant c.1105CT
onstructs were derived from pHCS3 expression plasmid.15
he mutation was introduced into the wild-type expression
lasmid with GeneTailor Site–directed mutagenesis kit (In-
itrogen, Carlsbad, California) on the basis of manufacturer
rocedure. The sequences of mutagenic primers for c.1105
T were as follow—sense: 5=-gCTgCgTggTCATTCT-
CCCgACTCagTgC-3= and antisense: 5=-gCAgAATgAC-
ACgCAgCACTggCCCTCCT-3=.
For the purpose of eukaryotic expression both the wild-
ype and c.1105 CT containing CBS were cloned into
TRE2hyg vector (Clontech Laboratories, Mountain View,
alifornia). The presence of c.1105 CT and the absence of
dditional mutations in the entire coding CBS sequence of
he c.1105C>T (p.R369C) mutation
Comments Reference
A sibpair diagnosed at 33 and 27 years of age,
respectively. The older sister was symptom
free, the younger brother had severe
psychiatric disease. Plasma tHcy
concentrations in these 2 patients were 245
and 130 mol/L before, and 8 and 18 mol/L
after pyridoxine administration (40 mg/d),
respectively.
14
The patient manifested by pulmonary embolus at
the age of 23 years after the birth of her son.
She was ascertained by family screening at 24
years of age since her son, who inherited from
her the 533del18 mutant allele, was diagnosed
with CBS deficiency.
4
Severely affected patient with ectopic lenses,
other connective tissue abnormalities,
thromboembolism and psychosis but without
mental retardation, age of diagnosis is not
given. The relative contribution of the 2
mutations linked in cis to the severe
inactivation of CBS enzyme has not been
determined.
13
nified by “c.”) or of the predicted amino acid substitution (signified by “p.”).
iveness is defined as decrease of plasma tHcy below 50 or 60 mol/L after pyridoxineing t
min
6†
ge (sig
esponshe pHCS3 and pTRE2hyg constructs were verified by
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oideoxy sequencing with ALF sequencer (Amersham Phar-
acia Biotech, Piscataway, New Jersey).
rokaryotic Expression
Both the wild-type and p.R369C CBS enzymes were
xpressed in DH5alpha cells (Gibco BRL, Carlsbad, Califor-
ia). The cells were grown at 37° C or 18° C, respectively, in
uper Optimal Broth (SOB) media supplemented with am-
icillin 100 g/mL. After the OD600 of cultures reached
0.5, the cells were induced with isopropyl -D-1-thioga-
actopyranoside (final concentration 0.33 mmol/L) and grown
or an additional 3 hours or overnight at 37° C or 18° C,
espectively. The pKK vector without CBS insert was used as
negative control. Lysates from Escherichia coli cell pellets
ere prepared by sonication in Tris-Cl buffer with addition of
rotease Inhibitor Cocktail suitable for use with bacterial cell
xtracts (Sigma Aldrich, St. Louis, Missouri).15 Concentra-
ion of protein in lysates was determined as described by
owry et al16 with bovine serum albumin used as a standard.
ll expressions were done in triplicate, and the numbers
hown in this article represent means.
ukaryotic Expression in CHO-K1 Cells
Because the CHO-K1 cells do not express endogenous
BS at significant levels, they are a suitable system for study-
ng CBS mutants. Two 75-cm2 flasks containing Chinese
amster ovary–derived cells that express the reverse tetracy-
line-controlled transactivator (BD Biosciences, San Jose,
alifornia) were transiently transfected with pTRE-2hyg
lasmid bearing either the wild-type or mutant human CBS
equences with Lipofectamine-2000 (Invitrogen, Carlsbad,
alifornia). The CBS expression was induced 4 hours after
ransfection with doxycycline (final concentration 200 ng/
L). About 20 hours after transfection the cells were har-
ested mechanically and pooled, cell extracts were prepared by
smotic lysis with phosphate buffer 30 mmol/L with PEE-
1 detergent,17 and protein concentration was determined as
escribed above. All expressions were done in triplicate, and
eans are shown in the article. For kinetic studies large-scale
xpression was carried out, and higher variability in the
mounts of mutant tetramers in lysates was observed (data not
hown).
BS Activity and Kinetics Measurement
The CBS activity was assayed at homocysteine 10
mol/L and serine 10 mmol/L by the previously published
rocedure15 with incubation at 37° C for 1 hour for E. coli
ysates and 4 hours for CHO lysates with the following
odification: mixture of unlabeled and 14C-labeled serine was
eplaced by 2H-labeled serine 10 mmol/L (Cambridge Iso-
ope Laboratories, Andover, Massachusetts) and the amount
f 2H-labeled cystathionine produced was determined by
C-MS-MS with a commercially available kit for amino acid
nalysis (EZ:faast; Phenomenex, Torrance, California) (Krijt
t al, unpublished data). 1
irth Prevalence of Homocystinuria in Central Europe: Frequency and P
f Mutation c.1105CT (p.R369C) in the Cystathionine Beta-Synthase GThe kinetic studies were performed in CHO lysates
approximately 30 to 40 g of total cellular protein in 50 L
eaction) incubated for 30 minutes at 37° C. The above-
escribed assay procedure was used maintaining one substrate
t saturating concentration (40 mmol/L and 20 mmol/L of
omocysteine and 2H-labeled serine, respectively) while using
he concentration of the other substrate of 0.31, 0.62, 1.25,
.5, 5, 7.5, 10, 12.5, 15, 20, 30, and 40 mmol/L. The Km and
max were calculated with KaleidaGraph software (Synergy
oftware, Reading, Pennsylvania).
estern Blot Analysis
For Western blot analysis, cell lysates containing total
rotein 10 g were electrophoresed on 4% to 15% gradient
ative polyacrylamide gels (BioRad precast gels) with Lae-
mli buffer system with or without SDS for SDS-PAGE and
ative-PAGE gel, respectively. The separated proteins were
ransferred onto polyvinylidene difluoride membrane (Immo-
ilon-P; Millipore, Billerica, Massachusetts) with semi-dry
lotting transfer technique. After transfer and overnight
locking of nonspecific binding sites with 5% non-fat dry
ilk, the membrane was incubated with immunopurified
nti-CBS antibody diluted 1:5000 in 3% bovine serum albu-
in in 1  phosphate-buffered saline solution (PBS) for 1
our. After a series of washes the membrane was subse-
uently incubated with secondary anti-rabbit IgG antibody
onjugated with HRP for 30 minutes (Pierce, Rockford,
llinois); the secondary antibody was diluted 1:30 000 in
% non-fat dry milk dissolved in 1  PBS/0.2% Tween 20.
fter a second series of washes the signal was visualized
sing the West Pico Super Signal system (Pierce Biotech-
ology, Rockford, Illinois) followed by bioimaging system
hemiGenius-Q (Syngene Inc, Frederick, Maryland) with
ooled CCD camera. The amount of tetramers and high-
olecular weight aggregates were quantified with Gene
ools software (Syngene Inc).
tatistical Methods
Expected birth prevalence was calculated on the basis of
ardy-Weinberg equilibrium with a model published previ-
usly10 with added frequency of the c.1105CT alleles. Con-
dence intervals of estimates were calculated with S-plus
Tibco Software, Inc, Palo Alto, California) and R software.
RESULTS
requency of the c.1105C>T Mutation and Expected
irth Prevalence of Homocystinuria
We detected six c.1105CT heterozygotes among 600
nselected Czech newborns; 1 individual was present in the
ohemian cohort and 5 in the Moravian cohort, respectively.
he observed allelic frequency of c.1105CT is 0.005
95%CI 0.0018-0.011), which is similar to that observed in
orway.12 Assuming Hardy-Weinberg equilibrium the ex-
ected birth prevalence of homozygotes for this mutation is
:40 000 (95%CI 1:8000-1:295 000). We have previously es-
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4imated incidence of homocystinuria in the Czech Republic
ith a composite model.10 In the model we have combined
irect detection of 2 mutant alleles in unselected newborn
lood samples with an inferred population frequency of 8
dditional mutant alleles calculated from their number in
atients who were ascertained by biochemical screening dur-
ng a 20-year period. After adding the data on c.1105CT
rom this study into the above-mentioned composite model,
he expected birth prevalence of homocystinuria in the Czech
epublic increased to 1:15 500 newborns (95% CI 1:7500-1:
8 000).
n Silico Analyses of the p.R369C Mutant
Arginine 369 is located in the beta strand 11 at a
imer-dimer interface of the CBS enzyme.18 In their 3-di-
ensional model of full-length CBS, Yamanishi et al19 pre-
icted that this mutation abolishes an ionic interaction with
506 residue located in the carboxyterminal regulatory CBS
omain, suggesting possible destabilization of tertiary struc-
ure. Analysis with Clustal-W and a series of CBS orthologs
btained from NCBI database showed that arginine 369 is
ighly conserved in mammals, and in other organisms, this
ositively charged amino acid may be replaced by positively
harged lysine or uncharged tyrosine, valine, leucine, methi-
nine or asparagine residues but not by cysteine (data not
hown). This imperfect conservation of arginine in position
69 of the CBS polypeptide during evolution suggests that
his amino acid residue is not absolutely critical for cystathi-
nine beta-synthase function. Taken together these computer-
imulated data suggest that the effect of this mutation on
nzyme function may be rather mild.
roperties of p.R369C Mutant Expressed in E. coli
The p.R369C mutant expressed at 37° C was present in
acterial extracts in amounts somewhat lower than the wild-
ype enzyme (66 % of CBS signal relative to the wild-type
pon analysis by denaturing SDS-PAGE/western blotting;
ata not shown). Most of these mutant enzyme molecules
isfolded, as demonstrated by the presence of only 8% of
orrectly folded tetrameric fraction of the p.R369C relative to
he wild-type CBS enzyme when non-denaturing conditions
or PAGE/Western blotting were used and data were nor-
alized for CBS abundance (Figure). The relative activity—
hat is, specific activity normalized for the abundance of
etramers—of the p.R369C mutant was decreased to 34% of
he wild-type (Table II).
It was shown previously20 that lower expression tem-
erature may facilitate the attainment of correct tertiary and
uaternary structure of misfolding-prone mutants. Indeed,
olding and assembly of mutant p.R369C polypeptide chains
xpressed at 18° C improved substantially as the bacterial
xtracts contained 23% of tetramer compared with wild-type
nd the relative activity simultaneously increased to 67%
Table II). To examine whether the p.R369C mutation may
lter the response to the natural allosteric activator of CBS— f
34 Janošík et al-adenosylmethionine (SAM)—we measured the catalytic
ctivity of the mutant expressed at 18° C in the absence and
resence of 1 mmol/L SAM. The activity of the mutant
ncreased 4.4 times in the presence of SAM, which is similar
o the increase of 5.7 for the wild-type enzyme; these data
emonstrate that the mutant enzyme retains its normal allo-
teric activation by S-adenosylmethionine.
The above data show that the p.R369C CBS mutant is
ntrinsically prone to misfolding with simultaneous loss of
ctivity, and that this property may be reversed by folding
ermissive conditions. Moreover, the expression studies dem-
nstrated that even the correctly folded and assembled tet-
amers exhibit only 34% to 67% relative activity per tetramer
mount compared with the wild-type enzyme. It was shown
reviously that despite their limitations the prokaryotic ex-
ression systems permit examination of intrinsic properties of
utant enzymes such as cytosolic phenylalanine hydroxylase,
nd expression in mammalian systems mimics more faithfully
he in vivo situation in human beings.21 Therefore we subse-
uently tested the properties of the mutant enzyme in a
ammalian system.
roperties of p.R39C Mutant Expressed
n CHO-K1 Cells
The p.R369C mutant expressed in mammalian cells
as present in amounts similar to the wild-type enzyme
105% of the wild-type enzyme when assessed by Western
lotting under denaturing conditions, data not shown). Sur-
risingly, the amounts of correctly folded tetramers and
igher order oligomers were slightly increased to 129% com-
ared with wild-type enzyme after correction for the CBS
bundance. However, the relative activity of these correctly
igure. Quaternary structure of p.R369C mutant under different
xpression conditions. The p.R369C mutant was expressed in both E. coli
nd CHO cell-based systems, crude extracts were electrophoresed in
radient polyacrylamide gels under non-denaturing conditions followed by
estern blotting (see Methods for details). A representative gel is shown,
he sharply demarcated fractions (CBS)4, (CBS)8, or (CBS)12 contain 4, 8,
r 12 CBS subunits, respectively; the smear in the high molecular weight
raction contains misfolded CBS. The individual lanes contain either the
.R369C mutant (M), wild-type CBS (WT), or blank (B, i.e. either E. coli
ransformed with empty vector or CHO cells transfected with empty
ector pTRE2hyg, respectively). The line “Average amount of tetramers/
ligomers” shows the relative amounts of the sum of correctly folded
utant tetramers and oligomers relative to the wild-type CBS enzyme,
ata are means of 3 independent expressions with SD in parentheses.olded mutant oligomers was decreased to 54% of the wild-
The Journal of Pediatrics • March 2009
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oype tetramers (Table II). Taken together the net effect of the
.R369C substitution on quaternary structure and activity
ppears to be moderate in mammalian cells.
All experiments showed that despite varying extent of
orrect folding in either the mammalian or prokaryotic system
he relative activity of the p.R369C mutant is similarly de-
reased to about half of the wild-type enzyme. Such behavior
f the p.R369C mutant is expected to result from altered
inetic properties. Therefore we determined the Michaelis
onstant Km for both substrates and we measured the Vmax of
eaction in crude CHO cell extracts. The p.R369C mutant
xhibited Km for serine and homocysteine similar to Km of the
ild-type CBS (Table II). In contrast the Vmax of the mutant
as reduced to 29% of the wild-type enzyme and to 55% when
orrected for the abundance of tetramers in samples that were
sed for kinetic studies. Considering the limitations of analyses
n crude extracts all these data suggest that the p.R369C
utant does not have lower affinity for its 2 substrates but
hat the velocity of the reaction is approximately halved.
DISCUSSION
The surprisingly high frequency of the c.1105CT
llele among Norwegian newborns suggests that this CBS
utation may be the most common cause of homocystinuria
n North Europeans.12 However, functional studies indicated
hat it may only be a frequent neutral polymorphism, al-
hough the authors discussed a possibility that the yeast may
ot model this mutation properly.14 Because detailed func-
ional studies and data on frequency in other populations have
een lacking, we aimed in our study at exploring the proper-
ies of p.R369C mutant enzyme and at determining the
revalence of the c.1105CT allele in another European
opulation.
From clinical standpoint the question whether the
able II. Catalytic activity and kinetic properties of t
Specific activity in crude extracts (nmol cystathionine/mg tot
cellular protein/hour)*
E. coli 37° C
E. coli 18° C
CHO-K1 37° C
Relative activity in crude extracts (specific activity corrected
for tetramer abundance, in % of wild-type enzyme)
E. coli 37° C
E. coli 18° C
CHO-K1 37° C
Kinetic properties of wild-type and p.R369C mutant enzyme
in crude extracts after expression in CHO-K1 cells†
Km serine (mmol/L)
Km homocysteine (mmol/L)
Vmax (nmol/h/mg total cellular protein/)
Normalized Vmax (nmol/h/arbitrary units of CBS tetramer)
Numbers shown are means of 3 independent expression experiments with SD.
Numbers shown are means of 2 independent experiments (with the exception of Km.1105CT mutation causes homocystinuria or whether it is s
irth Prevalence of Homocystinuria in Central Europe: Frequency and P
f Mutation c.1105CT (p.R369C) in the Cystathionine Beta-Synthase Gnly a functionally neutral genetic variant is of key impor-
ance. Three lines of evidence support the hypothesis that it is
ndeed pathogenic. First, this mutation was found at 1 pa-
ental allele in 2 independent patients with CBS deficiency
Table I; patients 1 and 2), demonstrating that the p.R369C
utant enzyme produced from the c.1105CT allele has
mpaired catalytic activity because it is not able to functionally
omplement the mutant protein synthesized from the other
arental allele. Second, the expression studies presented in
his article strongly suggest that the mutant enzyme is intrin-
ically prone to misfolding but more folding permissive con-
itions of mammalian cells enable formation of normal
mounts of tetramers; in human beings carrying this mutation
he tendency to misfold may only manifest under conditions that
isfavor folding. Third, regardless of the expression system, the
elative activity of p.R369C mutant normalized for tetramer
bundance is decreased to about one half of the wild-type
nzyme. We have shown that this low activity is not caused by
ltered binding of substrates but rather by a decreased velocity
f the enzymatic reaction.
The properties of mutant enzyme expressed in cells,
owever, cannot unequivocally answer the question whether
he p.R369C mutation is pathogenic in vivo. The evidence
as to come from clinical observations; however, there is a
carcity of reports on CBS-deficient patients carrying the
.1105 CT variant. This discrepancy between the numbers
f expected and reported homozygotes/compound heterozy-
otes for c.1105 CT may be due to several reasons, for
xample, (1) patients may die antenatally, (2) patients may
ave a phenotypically different disease, which does not re-
emble homocystinuria (such an example is the mutation
.V377I in mevalonate kinase gene22), (3) the disease mani-
ests in an unrecognized mild adult-onset form, or (4) patients
o not have any clinical symptoms at all. The late onset of
.R369C mutant
Wild-type CBS p.R369C mutant
142.7  27.2 2.8  2.2
85.5  27.0 13.1  0.4
111.1  39.7 71.2  27.3
100% 34%  26%
100% 67%  8%
100% 54%  24%
10.1 8.1
5.8 7.5
1715 500
100% 55%
ocysteine, which was determined only once).he p
alymptoms, lack of mental retardation, and of connective tis-
athogenicity
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4ue involvement, and pyridoxine responsiveness in the known
atients carrying the p.R369C mutation favor the latter 2
ypotheses of a mild to null phenotype, which possibly es-
apes diagnosis. It is puzzling that such individuals are not
eing reported among patients with moderate to severe hy-
erhomocysteinemia who had been ascertained during a
hrombophilia workout. In summary, it is conceivable that in
uman beings the p.R369C mutation is not functionally
eutral in vivo although severity and spectrum of clinical
onsequences is at present unknown; only future reports on
henotypic features in homozygotes and additional compound
eterozygotes carrying this mutation will resolve this issue.
The second aim of our study was to determine the
requency of c.1105 CT in another European population.
he 0.5% frequency of c.1105 CT alleles in predominantly
lavic population of the Czech Republic is similar to 0.8%
requency determined by Refsum et al12 in Norwegian new-
orns or 0.5% shown for 200 North American adult control
ubjects by Kim et al.14 Although data from other European
opulations are lacking, similar frequencies in unrelated Nor-
egians, Czechs, and North Americans suggest that this
ariant allele may be of ancient origin and that it may be
ommon in populations of European descent. This high pop-
lation frequency of mutant CBS alleles may have important
onsequences for newborn screening. The expected frequency
f homocystinuria because of 6 mutations in Norway12 and 11
utations in the Czech Republic (this study) are similarly
igh, being 1:6400 and 1:15 500, respectively. Provided that
.R369C is indeed pathogenic, the expected frequency of
omocystinuria in 2 European populations is similar to the
requency of other common inborn errors of metabolism such
s phenylketonuria or MCAD deficiency.7 Such frequency
nd encouraging efficacy of therapeutic interventions in early
etected patients with CBS deficiency (summarized in refer-
nce 2) rank thus CBS deficiency among suitable candidates
or an efficient newborn screening.
Unfortunately, the existing newborn screening pro-
rams for CBS deficiency are based on detecting moderately
o grossly elevated methionine concentrations by various tech-
iques, including tandem mass spectrometry. It has been
hown that patients may not be ascertained if higher cut-off
ethionine levels are used.23 Especially the pyridoxine-re-
ponsive forms, which are present in at least 50% of patients
ith homocystinuria,1 seem to escape diagnosis by newborn
creening programs.7 This is demonstrated by only a single
atient with pyridoxine-responsive homocystinuria detected
mong 36 Irish and U.S. patients that were ascertained in the
ewborn period.8,23 Total homocysteine measurement in
lood samples24 or dried blood spots25 may be a more reliable
pproach to detecting neonates with homocystinuria. Unfor-
unately, total homocysteine is not routinely analyzed in new-
orn screening programs because of the necessity of releasing
omocysteine from its bond to plasma proteins in an addi-
ional pre-derivatization reduction step. Because cystathi-
nine is decreased and methionine normal to increased in
BS deficiency, the addition of a cystathionine assay with
2
t
36 Janošík et alalculation of cystathionine-to-methionine ratio may be an
pproach for increasing the number of detected presymptom-
tic newborn patients with homocystinuria. The molecular
pidemiology data reported previously12,14,26 and in this study
hallenge our perception of homocystinuria as a rare disease
nd should stimulate a discussion on how to increase the
fficacy of newborn screening for homocystinuria in popula-
ions of European origin.
he authors would like to express their gratitude to Petra Mele-
ovská, MSc, Jana Kopecká, MSc, and Alena Dutá for technical help,
arkéta Pavlíková, MSc, for calculating the confidence intervals,
nd J. P. Kraus, PHD, for providing the anti-CBS antibodies.
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CARDIOVASCULAR SURGERY IN A CHILDREN’S HOSPITAL II. CYANOTIC LESIONS. A REVIEW OF
193 OPERATIONS
Ash R, Johnson J, Koop CE, Friedman S, Rashkind W. J Pediatr 1959;54:348-62
The knowledge gained by reviewing older articles provides both perspective for what we have accomplished in the
intervening years, and forces the reader to speculate on how these accomplishments have occurred. The article by Ash
et al provides an early recount of the progress made over an 11-year span of their attempts to address the problem of
infants and children with cyanotic congenital heart disease. In their experience of almost 200 operations, they describe
diagnostic and surgical approaches for patients with tetralogy of Fallot, tricuspid atresia, total anomalous pulmonary
venous connection, and complete transposition of the great arteries, as well as miscellaneous other conditions. They
report an overall surgical mortality rate of 11.6% with an additional 7.9% of late deaths. They reflect on what they could
do and also the frustration of what could not be done for many of these children.
Fifty years ago there had been many successful operations for repair of relatively simple congenital heart defects done
without cardiopulmonary bypass. The systemic to pulmonary shunt of Blalock and Taussig had been performed for 15
years and was the only effective palliation for some of these cyanotic problems. The first successful heart operation with
cardiopulmonary bypass was performed in 1953, although the application in infants would still be years away—requiring
more technological advances. Cardiac catheterization, the primary diagnostic tool 50 years ago, has become the primary
therapeutic tool for many lesions.
Technology and innovative thinking have been the driving forces in the past 50 years, which have led to a significant
expansion of the scope and results in the care of children with congenital heart disease. Today an operative mortality rate
of less than 2% is expected, with few late deaths.1 Challenges remain, but the future has never looked brighter for children
with congenital heart disease.
Richard A. Humes, MD
Division of Cardiology
Children’s Hospital of Michigan
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